SML3154
Topiroxostat
≥98% (HPLC)
别名:
4-[3-(4-Pyridinyl)-1H-1,2,4-triazol-5-yl]-2-pyridinecarbonitrile, 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, 5-(2-Cyano-4-pyridyl)-3-(4-pyridyl)-1,2,4-triazole, FYX 051, FYX-051
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C13H8N6
化学文摘社编号:
分子量:
248.24
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
N#CC1=NC=CC(C2=NNC(C3=CC=NC=C3)=N2)=C1
InChI
1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChI key
UBVZQGOVTLIHLH-UHFFFAOYSA-N
Biochem/physiol Actions
Topiroxostat (FYX-051) is an orally active and potent inhibitor of xanthine oxidoreductase (XOR). It appears that inhibition of XOR by topiroxostat is due to the formation a covalent linkage to molybdenum via oxygen in the hydroxylation reaction intermediate. Also, topiroxostat displayed a potent, non-covalent inhibition of XOR. It is approved for the treatment of gout and hyperuricemia in Japan.
orally active and potent inhibitor of xanthine oxidoreductase (XOR)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable